Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer

雄激素受体抑制可增加MHC I类分子的表达并改善前列腺癌的免疫反应

阅读:3
作者:Lisa N Chesner,Fanny Polesso,Julie N Graff,Jessica E Hawley,Alexis K Smith,Arian Lundberg,Rajdeep Das,Tanushree Shenoy,Martin Sjöström,Faming Zhao,Ya-Mei Hu,Simon Linder,William S Chen,Reed M Hawkins,Raunak Shrestha,Xiaolin Zhu,Adam Foye,Haolong Li,Lisa M Kim,Megha Bhalla,Thomas O'loughlin,Duygu Kuzuoglu-Ozturk,Junjie T Hua,Michelle L Badura,Scott Wilkinson,Shana Y Trostel,Andries M Bergman,Davide Ruggero ,Charles G Drake,Adam G Sowalsky,Lawrence Fong ,Matthew R Cooperberg ,Wilbert Zwart,Xiangnan Guan,Alan Ashworth,Zheng Xia ,David A Quigley ,Luke A Gilbert,Felix Y Feng # ,Amy E Moran #

Abstract

Immunotherapy options for immune cold tumors, like prostate cancer, are limited. We show that AR downregulates MHCI expression/antigen presentation and that AR inhibition improves T-cell responses and tumor control. This suggests that treatments combining AR inhibitors and checkpoint blockade may improve tumor immune surveillance and antitumor immunity in patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。